Fidelity Investments
APGE icon

Fidelity Investments’s Apogee Therapeutics APGE Stock Holding History

Fidelity Investments’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331M Sell
2,493,137
-6,769,154
-73% -$610M 0.01% 716
2026
Q1 		$780M Buy
9,262,291
+1,037,253
+13% +$75.3M 0.04% 365
2025
Q4 		$621M Buy
8,225,038
+1,308,576
+19% +$82.4M 0.03% 432
2025
Q3 		$275M Buy
6,916,462
+9,362
+0.1% +$357K 0.01% 721
2025
Q2 		$300M Sell
6,907,100
-586,526
-8% -$22.3M 0.02% 665
2025
Q1 		$280M Sell
7,493,626
-5,756
-0.1% -$223K 0.02% 671
2024
Q4 		$340M Sell
7,499,382
-3,100
-0% -$158K 0.02% 610
2024
Q3 		$441M Sell
7,502,482
-3,393
-0% -$163K 0.03% 522
2024
Q2 		$295M Buy
7,505,875
+761,973
+11% +$37M 0.02% 637
2024
Q1 		$448M Buy
6,743,902
+1,725,022
+34% +$75.3M 0.03% 493
2023
Q4 		$137M Buy
5,018,880
+579,082
+13% +$11.6M 0.01% 902
2023
Q3 		$89.6M Buy
+4,439,798
New +$97.8M 0.01% 1025

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Fidelity Investments's APGE Position: Q2 2026 in Review

Fidelity Investments reduced its Apogee Therapeutics (APGE) stake by 73% in Q2 2026, selling an estimated $610M and leaving 2,493,137 shares worth $331M. The position accounts for 0.01% of the portfolio, ranked #716.

Fidelity Investments first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $780M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Fidelity Investments held 2,493,137 shares of Apogee Therapeutics worth $331M as of Q2 2026.
  • Fidelity Investments sold 6,769,154 Apogee Therapeutics shares in Q2 2026, an estimated $610M.
  • Apogee Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #716 holding.
  • Fidelity Investments first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Fidelity Investments's Apogee Therapeutics position peaked at $780M in Q1 2026.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.